10-K/A: Eterna Therapeutics Files Amended 10-K to Correct Accounting Firm Consent Date

Eterna Therapeutics filed an amendment to its annual report to correct a typographical error in the date of the independent accounting firm's consent.

Summary

• Eterna Therapeutics Inc. filed an amendment to its annual report on Form 10-K for the fiscal year ended December 31, 2023.
• The sole purpose of this amendment is to correct a typographical error in the date within the consent of Grant Thornton LLP, the independent registered public accounting firm.
• The original Form 10-K was filed on March 14, 2024, and this amendment was filed on March 18, 2024.
• No other revisions were made to the company's financial statements or any other disclosures in the original Form 10-K.
• The amendment includes new certifications from the company's principal executive officer and principal financial officer.

Sentiment

Score: 7

Explanation: The document is a routine amendment to correct a minor error, which is a neutral event. The company is taking steps to ensure accuracy, which is a positive sign.

Positives

• The company is taking steps to ensure accuracy in its filings by correcting a typographical error.
• The amendment does not indicate any issues with the financial statements or other disclosures in the original filing.

Risks

• While the amendment is for a minor correction, any errors in filings can raise concerns about the company's attention to detail.
• The need for an amendment, even for a minor issue, could potentially impact investor confidence.

Management Comments

• Sanjeev Luther, President and Chief Executive Officer, certified that the report does not contain any untrue statement of a material fact.
• Sandra Gurrola, Senior Vice President of Finance, certified that the report does not contain any untrue statement of a material fact.

Industry Context

This type of amendment is not uncommon and is often a result of a minor error in the original filing. It is a standard process to correct such errors.

Comparison to Industry Standards

• The process of filing an amendment to correct errors is standard practice across all publicly listed companies.
• The nature of the error, a typographical error in the date of the accounting firm's consent, is a minor issue and does not indicate any significant problems with the company's financial reporting.

Stakeholder Impact

• The amendment is unlikely to have a significant impact on stakeholders as it is a correction of a minor error.

Key Dates

Keywords

Form 10-K, Amendment, Accounting Firm Consent, Financial Reporting, Grant Thornton LLP, Typographical Error, SEC Filing